Baseline And Post-Treatment Circulating Tumor Cell (Ctc) Counts With Prostate-Specific Membrane Antigen (Psma)-Targeted Radionuclide Therapy (Trt) In Men With Metastatic Castration-Resistant Prostate Cancer (Mcrpc).

Michael Sun,Justin M Lebenthal,Jones T. Nauseef,Muhammad Junaid Niaz,Sabrina Guervil,Escarleth Fernandez,Amie Patel,Angela Tan,Panagiotis J. Vlachostergios,Joseph Osborne,Ana M. Molina,Cora N. Sternberg,David M. Nanus,Neil Harrison Bander,Scott T. Tagawa

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 0|浏览45

暂无评分

摘要

158Background: CTC counts are an independent prognostic factor in men with mCRPC; certain changes following treatment (conversion from detectable to undetectable or unfavorable to favorable) are as...

查看译文

关键词

Prostate cancer,Circulating tumor cell,Glutamate carboxypeptidase II,Oncology,Medicine,Castration resistant,Internal medicine,Post treatment,Prognostic factor,Targeted radionuclide therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要